Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Operating Expenses

Last Annual Value

89.73M

3-Year CAGR

24%

5-Year CAGR

38%

10-Year CAGR

17%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Operating Expenses

TRML · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
89.73M
25.5%13.9%N/A 
152.77M
-21.6%13.1%N/A
179.97M
52.2%65.3%34.5%
119.39M
12.6%37.0%N/A
141.78M
8.9%12.4%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
110.19M
3.3%16.0%-8.0%
314.54M
-7.6%-3.1%N/A
438.47M
24.0%31.0%25.6%
110.12M
2.4%16.7%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98